---
schema_version: "secwatch.filing_event.v1"
accession: "0001013762-23-005230"
form_type: "8-K"
ticker: "JSPR"
cik: "0001788028"
company_name: "Jasper Therapeutics, Inc."
filed_at: "2023-10-20T23:59:59+00:00"
generated_at: "2026-06-09T18:47:44.487176+00:00"
event_type: "regulatory"
sentiment: "negative"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Jasper Therapeutics receives Nasdaq bid price deficiency notice; must regain compliance by Apr 15, 2024

## Summary
- Notice from Nasdaq: common stock bid price below $1.00 for 30 consecutive business days.
- Company has 180 days, until April 15, 2024, to regain compliance with Rule 5550(a)(2).
- If bid price closes at $1.00 or more for ten consecutive days, Nasdaq will confirm compliance.
- Company may consider a reverse stock split to cure deficiency; no assurance of regaining compliance.
- Trading of common stock (JSPR) and warrants (JSPRW) continues on Nasdaq Capital Market.

## SEC filing metadata
- accession: 0001013762-23-005230
- form_type: 8-K
- ticker: JSPR
- cik: 0001788028
- company_name: Jasper Therapeutics, Inc.
- filed_at: 2023-10-20T23:59:59+00:00
- event_type: regulatory
- sentiment: negative
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 3.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1788028/000101376223005230/0001013762-23-005230-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1788028/000101376223005230/ea186965-8k_jasper.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001013762-23-005230
- JSON: https://secwatch.observer/filing/0001013762-23-005230.json
- Plain text: https://secwatch.observer/filing/0001013762-23-005230.txt

## Key facts
- Listing & Compliance Notices
  Jasper Therapeutics, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)(ii)).
  - Exchange: nasdaq
  - Notice: deficiency notice
  - Deficiency: minimum bid price
  - Rules: 5550(a)(2), 5810(c)(3)(A)(ii)
  source text: October 18, 2023, Jasper Therapeutics, Inc. (the “Company”) received written notice (the “Notice”) from The Nasdaq Stock Market LLC (“Nasdaq”) indicating that, for the last thirty consecutive business days, the bid price for the Company’s voting common stock had closed below the minimum $1.00 per share requirement for continued listing on the Nasdaq Capital Market under Nasdaq Listing Rule 5550(a)(2) (“Rule 5550(a)(2)”). In accordance with Nasdaq Listing Rule 5810(c)(3)(A)(ii), the Company has been provided an initial period of 180 calendar days, or until April 15, 2024, to regain compliance.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1788028/000101376223005230/0001013762-23-005230-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.